Cel Sci (CVM) Capital Expenditures (2010 - 2025)
Cel Sci (CVM) posted Capital Expenditures of $5155.0 for Q3 2025, down 84.36% sequentially from $32954.0 in Q4 2024, and down 73.9% YoY from $19753.0 in Q3 2024.
Cel Sci (CVM) Capital Expenditures (2010 - 2025) Analysis & Trends
Cel Sci has reported Capital Expenditures for 15 years, with the latest figure at $5155.0 in Q3 2025.
- Quarterly Capital Expenditures fell 73.9% year-over-year to $5155.0 in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $5155.0 (down 93.23% YoY) and the FY2025 annual result came in at $38109.0, down 59.83% from the prior year.
- Capital Expenditures declined to $5155.0 in Q3 2025 per CVM's latest filing, from $32954.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $3.5 million in Q1 2021 and troughed at $5155.0 in Q3 2025.
- A 5-year average of $466618.5 and a median of $53580.0 in 2022 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 434.46% in 2021, down 99.46% in 2021.
- Over 5 years, Capital Expenditures stood at $17036.0 in 2021, then soared by 214.51% to $53580.0 in 2022, then dropped by 3.6% to $51650.0 in 2023, then sank by 36.2% to $32954.0 in 2024, then slumped by 84.36% to $5155.0 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered $5155.0, $32954.0, and $19753.0 for Q3 2025, Q4 2024, and Q3 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 251.02 Mn |
| 10 | Cel Sci | 2.18 Mn | -4.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5,155.00 |
| Sep 30, 2025 | 5,155.00 |
| Dec 31, 2024 | 32,954.00 |
| Dec 31, 2024 | 32,954.00 |
| Sep 30, 2024 | 19,753.00 |
| Sep 30, 2024 | 19,753.00 |
| Jun 30, 2024 | 23,472.00 |
| Jun 30, 2024 | 23,472.00 |
| Dec 31, 2023 | 51,650.00 |
| Dec 31, 2023 | 51,650.00 |
| Jun 30, 2023 | 196,860.00 |
| Jun 30, 2023 | 196,860.00 |
| Mar 31, 2023 | 111,452.00 |
| Mar 31, 2023 | 111,452.00 |
| Dec 31, 2022 | 53,580.00 |
| Dec 31, 2022 | 53,580.00 |
| Sep 30, 2022 | 16,066.00 |
| Sep 30, 2022 | 16,066.00 |
| Jun 30, 2022 | 70,965.00 |
| Jun 30, 2022 | 70,965.00 |